Solventum Corporation $SOLV Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC grew its stake in Solventum Corporation (NYSE:SOLV) by 20.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,588,728 shares of the company’s stock after buying an additional 763,308 shares during the period. Geode Capital Management LLC owned 2.65% of Solventum worth $362,375,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Hilltop National Bank boosted its holdings in shares of Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum in the 3rd quarter valued at $25,000. JNBA Financial Advisors boosted its holdings in shares of Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new position in shares of Solventum in the 2nd quarter valued at $28,000. Finally, City State Bank boosted its holdings in shares of Solventum by 166.7% in the 4th quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after buying an additional 240 shares in the last quarter.

Solventum Stock Performance

Shares of SOLV opened at $75.97 on Tuesday. The company has a 50-day simple moving average of $69.75 and a 200-day simple moving average of $75.08. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The company has a market capitalization of $13.16 billion, a PE ratio of 9.31, a P/E/G ratio of 1.16 and a beta of 0.59. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $88.20.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business’s revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Insider Activity

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was purchased at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the acquisition, the director owned 5,039 shares of the company’s stock, valued at $342,803.17. The trade was a 41.39% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 0.24% of the stock is owned by corporate insiders.

Analyst Ratings Changes

SOLV has been the subject of several research analyst reports. Stifel Nicolaus lowered their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and set a $89.00 price target on shares of Solventum in a research note on Wednesday, May 6th. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Piper Sandler decreased their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Finally, Rothschild & Co Redburn assumed coverage on shares of Solventum in a research note on Tuesday, March 24th. They set a “sell” rating and a $60.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.